Neil Bailey

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (6)

Geoffrey Shouse

Assistant Clinical Professor

City Of Hope National Medical Center

UNITED STATES

View details

Heiko Konig

Associate Professor

UNITED STATES

View details

Michael Spinner

Clinical Assistant Professor of Medicine (Hematology/Oncology)

University of California, San Francisco

UNITED STATES

View details

Muhammad Hamid

Assistant Professor

The University of Tennessee Health Science Center Health Sciences Library

UNITED STATES

View details

David Bond

Associate Professor

Ohio State University

UNITED STATES

View details

Christopher Strouse

Iowa State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Neil Bailey

Research Interests

Explore related searches

Contact this professor

Articles (13)

The Evolution of Burden of Novel Cell Therapy Trials on Research Operations

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma.

Outpatient CAR T Cell Therapy Is Safe and Feasible in Patients with Lymphoma Treated in Non-University Medical Centers: A Multicenter, Retrospective Analysis

Real-World Outcomes of CD19 CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Abstract A27: Impact of a validated composite comorbidity score on outcomes in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): A multicenter real-world evidence (RWE) study

The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome

A Prospective Randomized Trial Comparing Conditioning with Either BEAM or High-Dose Melphalan Prior to Autologous Transplantation for Patients with Multiple Myeloma: An Evaluation of Interim Safety in Early Recovery Phase

Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Collaborators (6)

Geoffrey Shouse

Heiko Konig

Michael Spinner

Muhammad Hamid

David Bond

Christopher Strouse

Make your next move.